Abstracts
PDB8 WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?
Pirk O 1 , Ratzmann KP 2 , Carels J 3 , Bramlage P 4 , Kirch W 4 1 Fricke & Pirk GmbH, Nuremberg, Germany; 2 Diabetische Schwerpunktpraxis, Berlin, Germany; 3 Sanofi-Synthelabo, Berlin, Germany; 4 Medizinische Fakultaet Carl Gustav Carus der Technischen Universitaet Dresden, Dresden, Germany OBJECTIVES: Type-2 diabetes is a major health problem. 30% of all patients being on dialysis suffer from a diabetic Endstage Renal Disease (ESRD). The Angiotensin-2-Receptor-Blocker (ARB) Irbesartan has proven its capability to prevent or delay an ESRD. Based on the results of the multicentre double-blind, randomized, placebo-controlled Irbesartan Diabetic Nephropathy Trial (IDNT) the presented study aims to show that a treatment of renal diseases in hypertensive type-2 diabetics with the ARB Irbesartan is cost saving for the German health care system. METHODS: A cost-effectiveness analysis from the German payers' perspective was conducted taking direct costs into account. 1715 type-2 diabetics with hypertension and limited renal function were included in IDNT (2.6 years, subgroup with 300 mg/d Irbesartan). The patient number needed to treat (NNT) to prevent one ESRD was the efficacy parameter for this analysis. Public sources were used for cost data and information on dialysis and transplantation in diabetics with ESRD. Actual drug prices were used taking into account discounts and co-payments effective in Germany due to new legislation since January 2004. Due to conservative calculation no discounting was performed, follow-up treatment costs were not included. RESULTS: The NNT for the primary endpoint ESRD calculated to 28 during the study period of 2.6 years in IDNT. That means additional treatment costs of €25,007.-lead to one prevented ESRD (incremental cost-effectiveness-ratio). The prevented ESRD (82% dialysis, 18% transplantation) is worth €45,766.-which shows a benefit for Irbesartan treatment of €20,758.-after 2.6 years or €7984.
-per year assuming a linear trend towards delay in ESRD. A sensitivity analysis stated the robustness of the data. CONCLUSIONS: Based on epidemiologic data our results suggest savings for the German health care system of €3.2 billion after 2.6 years if annually additional €681 million were invested in the treatment of type-2 diabetics with Irbesartan.
PDB9 THE VALUE OF ORAL MONOTHERAPY ALTERNATIVES IN THE FIRST-LINE TREATMENT OF TYPE-2 DIABETES MELLITUS
Tilden D 1 , Stynes G 1 , Swift M 2 , Cockle S 1 , Haycox A 3 , Aristides M 1 1 M-TAG Limited, Hammersmith, UK; 2 Takeda UK Limited, High Wycombe, UK; 3 University of Liverpool, Liverpool, UK OBJECTIVES: To construct a lifetime model evaluating potential health benefits and costs applying to Scottish Type-2 diabetes mellitus patients initiating first-line oral monotherapy, for whom metformin is inappropriate because of contra-indications or intolerance. When lifestyle modification (diet and exercise) affords inadequate glycaemic control, these patients currently have no alternative to sulphonylurea (SU) therapy. The model compared novel agent pioglitazone (PIO) versus generic SU treatment. METHODS: A decision-analytic Markov model was constructed using published (UKPDS) cost data for diabetes management and co-morbidity treatment. Three prospective treatment pathways were explored: first-line PIO/second-line PIO + SU combination/third-line insulin; first-line SU/secondline PIO + SU combination/third-line insulin; and first-line SU/second-line insulin. The model incorporated efficacy evidence of glycaemic control under PIO and SU, measured as initial HbA1c improvements and the rate of disease progression in terms of HbA1c (the coefficient of failure). RESULTS: Patients treated with PIO achieved better HbA1c control and improved serum lipid profiles, which translated into fewer diabetic complications, better quality of life and improved overall survival. Additional drug costs of PIO over SU were partly offset by lower costs to treat and manage diabetes complications, and delayed insulin therapy. The estimated incremental cost per QALY gained of PIO was £2415 compared to SU (when followed by secondline PIO/SU and third-line insulin therapy). The incremental cost per QALY gained of PIO was £1514 compared to SU (when followed by second-line insulin therapy). CONCLUSIONS: Clinical trial evidence indicated superior glycaemic (HbA1c) control in patients treated with PIO, in comparison with those treated with SU. The model showed that PIO is a cost-effective intervention and thus a valuable addition to first-line treatment options for patients intolerant and/or contra-indicated to metformin. Importantly, initiating PIO as second-line combination treatment after first-line SU in this patient group was less efficient than providing PIO monotherapy in a first-line setting.
